Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

被引:20
作者
Ruhlmann, Christina H. [1 ]
Herrstedt, Jorn [1 ]
机构
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
关键词
adverse events; aprepitant; CYP3A4; fosaprepitant; MK-0869; neurokinin(1) receptor antagonist; safety; tolerability; RECEPTOR ANTAGONIST APREPITANT; ORAL NK1 ANTAGONIST; ANTIEMETICS PROVIDES PROTECTION; PLACEBO-CONTROLLED TRIAL; CISPLATIN-INDUCED EMESIS; HIGH-DOSE CISPLATIN; DOUBLE-BLIND; NEUROKININ-1; ANTAGONIST; CYTOCHROME-P450; 3A4; MULTIPLE CYCLES;
D O I
10.1517/14740338.2011.563235
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Aprepitant is the only neurokinin (NK1) receptor antagonist (RA) approved for prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant is co-administered with a 5-HT3 RA and a corticosteroid. Although aprepitant is safe, in most clinical settings potential drug-drug interactions need to be considered before prescription. Areas covered: This article thoroughly reviews aprepitant and, in particular, clinically relevant safety aspects of the drug. The literature review was performed using Medline with the following search terms: adverse events, aprepitant, chemotherapy, CYP3A4, MK-0869, neurokinin1 receptor antagonist, safety and tolerability. Expert opinion: The recommended antiemetic regimen of aprepitant, a 5-HT3 RA and a corticosteroid is safe. The combination of aprepitant, a 5-HT3 RA and dexamethasone is now the gold standard of antiemetic treatment in prevention of CINV induced by HEC, or by the combination of an anthracycline and cyclophosphamide. The intravenous formulation of aprepitant used as a single dose is expected to be of benefit to cancer patients.
引用
收藏
页码:449 / 462
页数:14
相关论文
共 64 条
[61]   THE TACHYKININ NK(1) RECEPTOR ANTAGONIST CP-99,994 ATTENUATES CISPLATIN-INDUCED EMESIS IN THE FERRET [J].
TATTERSALL, FD ;
RYCROFT, W ;
HARGREAVES, RJ ;
HILL, RG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 250 (01) :R5-R6
[62]   Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869 - A randomized controlled trial [J].
Van Belle, S ;
Lichinitser, MR ;
Navari, RM ;
Garin, AM ;
Decramer, MLA ;
Riviere, A ;
Thant, M ;
Brestan, E ;
Bui, B ;
Elridge, K ;
De Smet, M ;
Michels, N ;
Reinhardt, RR ;
Carides, AD ;
Evans, JK ;
Gertz, BJ .
CANCER, 2002, 94 (11) :3032-3041
[63]   Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy [J].
Warr, DG ;
Hesketh, PJ ;
Gralla, RJ ;
Muss, HB ;
Herrstedt, J ;
Eisenberg, PD ;
Raftopoulos, H ;
Grunberg, SM ;
Gabriel, M ;
Rodgers, A ;
Bohidar, N ;
Klinger, G ;
Hustad, CM ;
Horgan, KJ ;
Skobieranda, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2822-2830
[64]   The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human [J].
Wu, Y ;
Loper, A ;
Landis, E ;
Hettrick, L ;
Novak, L ;
Lynn, K ;
Chen, C ;
Thompson, K ;
Higgins, R ;
Batra, U ;
Shelukar, S ;
Kwei, G ;
Storey, D .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 285 (1-2) :135-146